

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb20410</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>Gene Expression and Levels of TGF-B in PBMC is Associated with Severity of Symptoms in Chronic Heart Failure</article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Saadati</surname><given-names>Samaneh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Eskandari</surname><given-names>Vajiheh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Rahmani</surname><given-names>Farzaneh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Mahmoudi</surname><given-names>Mohammad Jafar</given-names></name></contrib><aff>Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff>Department of Clinical Biochemistry, Radiopharmacy Lab, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Rahnemoon</surname><given-names>Zahra</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Rahmati</surname><given-names>Zahra</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Gorzin</surname><given-names>Fatemeh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Hedayat</surname><given-names>Mona</given-names></name></contrib><aff>Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Amirzargar</surname><given-names>Ali Akbar</given-names></name></contrib><aff>Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR      , Tehran, Iran</aff><aff>Department of Immunology, School of Public Health, Tehran University of Medical Sciences      , Tehran, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Rezaei</surname><given-names>Nima</given-names></name></contrib><aff>Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran      , Tehran, Iran</aff></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>12</volume>
      <issue>2</issue>
      <fpage>132</fpage>
      <lpage>134</lpage>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>10</month>
          <year>2019</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>11</month>
          <year>2019</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p&gt;Background: TGF-&amp;beta;1 is known to promote cardiac remodeling and fibrosis during Congestive Heart Failure (CHF). In this study, an attempt was made to investigate expression of Transforming Growth Factor beta1 (TGF-&amp;beta;1) and relative expansion or contraction of regulatory T-cell (Tregs) population in peripheral blood of patients with Chronic Heart Failure (CHF).&lt;/p&gt;

&lt;p&gt;Methods: Real-time PCR assay was used to investigate expression and post-stimulation levels of TGF-&amp;beta;1 in cell culture supernatant of Peripheral Blood Mononuclear Cells (PBMC) of 42 patients with CHF and 42 controls. Flow cytometry was used to identify relative counts of CD4&lt;sup&gt;+&lt;/sup&gt;CD25&lt;sup&gt;+&lt;/sup&gt;FoxP3&lt;sup&gt;+&lt;/sup&gt; Tregs.&lt;/p&gt;

&lt;p&gt;Results: PBMCs in patients with CHF expressed higher levels of TGF-&amp;beta;1 compared to controls. Post-stimulation levels of TGF-&amp;beta;1 expression were significantly higher in New York Heart Association (NYHA) functional class IV patients compared to stage I patients. Tregs were significantly expanded in PBMC in CHF, while the CD4&lt;sup&gt;+&amp;shy;&lt;/sup&gt; helper T-cells were unchanged. Treg expansion was more significant in NYHA functional class I patients compared to class IV patients.&lt;/p&gt;

&lt;p&gt;Conclusion: Expansion of Treg population in CHF provides an extrinsic source for TGF-&amp;beta;1 production to induce reactive fibrosis and cardiac remodeling. Relative decrease in Treg population at advanced stages of CHF is indicative of a loss of regulatory characteristics in these cells and unopposed proinflammatory milieu.&amp;nbsp;&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
